Literature DB >> 14561138

Regulation of in vitro fibril formation of synuclein mutant proteins by Hsp104p.

Byungmoon Kong1, Young Kee Chae, Kyunghee Lee.   

Abstract

Hsp104p, as an anti-oxidative protector of ROS generation, was examined to inquire if it prevents aggregation of synuclein mutants, A30P or A53T upon aging, in vitro. The role of Hsp104p was also addressed in dissociation of pre-formed aggregates of synuclein mutants. Significant protection in fibril formation was observed by wild-type Hsp104p regardless of ATP presence, not by mutant Hsp104p. To a lesser extent, the dissociation effect of wild-type Hsp104p was observed only in the presence of ATP. These results will be discussed in relation to the development of an antioxidant approach to prevent amyloid fibril formation in several neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561138     DOI: 10.2174/0929866033478717

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  3 in total

1.  Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.

Authors:  Christophe Lo Bianco; James Shorter; Etienne Régulier; Hilal Lashuel; Takeshi Iwatsubo; Susan Lindquist; Patrick Aebischer
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 2.  Prion proteostasis: Hsp104 meets its supporting cast.

Authors:  Elizabeth A Sweeny; James Shorter
Journal:  Prion       Date:  2008-10-22       Impact factor: 3.931

Review 3.  From the baker to the bedside: yeast models of Parkinson's disease.

Authors:  Regina Menezes; Sandra Tenreiro; Diana Macedo; Cláudia N Santos; Tiago F Outeiro
Journal:  Microb Cell       Date:  2015-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.